Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2351 - 2375 of 15655 in total
Proxibarbal is a derivative of barbiturates, which has been used to treat migraines. Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia .
Approved
Matched Categories: … Hypnotics and Sedatives …
Clove oil is obtained by extraction from the dried flower buds of the clove plant. Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities. The antioxidant and antimicrobial...
Approved
Nutraceutical
Matched Description: … The antioxidant and antimicrobial activity of clove is higher than that of many fruits, vegetables, and ... _gallic acid_ and has great potential for pharmaceutical, cosmetic, food and agricultural applications ... plant represents one of the richest source of phenolic compounds such as _eugenol_, _eugenol acetate_ and
Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy. An adeno-associated virus is a small virus that infects humans and other primates. It is not pathogenic and it causes a very mild immune response. This type of virus is vastly used as vectors for gene therapy because they can...
Approved
Matched Description: … cell integrating just the carried genes into the host genome without fully integrating into the genome ... It is not pathogenic and it causes a very mild immune response. ... [L1094] An adeno-associated virus is a small virus that infects humans and other primates. …
Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue...
Approved
Investigational
Withdrawn
Matched Iupac: … ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-[({4-[(Z)-N'-hydroxycarbamimidoyl]phenyl}methyl)carbamoyl]azetidin …
Matched Description: … intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and ... would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and
Matched Categories: … Blood and Blood Forming Organs …
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Approved
Investigational
Matched Categories: … Drugs for Acid Related Disorders ... Alimentary Tract and Metabolism ... omeprazole, amoxicillin and rifabutin ... Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) …
Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta...
Approved
Investigational
Matched Description: … Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface ... , reducing potassium conductance and causing depolarization of the membrane. ... Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH) . Mecasermin rinfabate is similar to DB01277 in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin rinfabate however,...
Approved
Matched Description: … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in ... patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …
Poloxamer 188 (P188) is a nonionic block linear copolymer that exhibits rheologic, anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models . Composed of two hydrophilic side-chains attached to a hydrophobic center core , its average molecular weight is 8400 Daltons. P188 was originally approved by the FDA in...
Approved
Investigational
Matched Description: … The ability of P188 in attenuating membrane damage and cell injury has been demonstrated in a variety ... mouthwash, and used in various cosmetic, industrial and pharmaceutical applications. ... of _in vivo_ and _in vitro_ models [A27218]. …
Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
Approved
Investigational
Matched Description: … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug ... thus poorer overall survival and higher risk of relapse. ... anthracycline induction and standard cytarabine consolidation, followed by a maintenance monotherapy …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada...
Approved
Investigational
Matched Iupac: … (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(1-methyl-1H-1,2,4-triazol-5-yl)-2,3,10-triazatricyclo[7.3.1.0 …
Matched Description: … (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and ... L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and ... [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.
Approved
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale,...
Approved
Investigational
Matched Description: … Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Approved
Illicit
Investigational
Withdrawn
Matched Description: … In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …
A direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Approved
Matched Description: … It may cause gastrointestinal distress and tachycardia. …
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS). Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents...
Approved
Investigational
Matched Description: … Food and Drug Administration (FDA) in March 2005. ... Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the ... manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and
Matched Categories: … Nucleosides and Nucleotides ... Nucleoside and Nucleotide Reverse Transcriptase Inhibitors …
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other...
Approved
Investigational
Matched Description: … and vomiting. ... Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting ... Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. …
Matched Categories: … Alimentary Tract and Metabolism ... Antiemetics and Antinauseants …
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Approved
Matched Description: … [A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Approved
Matched Iupac: … N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2 …
Matched Description: … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase …
Matched Categories: … lamivudine and raltegravir …
Calcium carbimide, sold as the citrate salt, is an alcohol-sensitizing agent. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. Calcium carbimide was conceived as an alternative for the treatment of...
Approved
Withdrawn
Matched Description: … [A31516] This drug was developed by Lederle Cyanamid Canada Inc and approved for marketing in Canada …
Sinapultide (also known as KL4 peptide) is a synthetic protein used to mimic human lung surfactant protein B. This protein has a weight of 2469.40. Sinapultide is a 21-residue peptide made up of lysine (K) and leucine (L) residues with the sequence KLLLLKLLLLKLLLLKLLLLK (KL4), in aqueous dispersion with the phospholipids...
Approved
Matched Iupac: … hexanamido]-4-methylpentanamido]-4-methylpentanamido]-4-methylpentanamido]-4-methylpentanamido]hexanoic acid
Matched Description: … palmitic acid, to create the drug [lucinactant]. ... Surfactant replacement therapy has been commonly used to prevent and treat RDS in these newborns and ... [L2502] Sinapultide is a 21-residue peptide made up of lysine (K) and leucine (L) residues with the …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Approved
Investigational
Matched Iupac: … N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene- …
Matched Description: … -2 and high risk primary and secondary myelofibrosis. ... Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the...
Approved
Investigational
Vet approved
Matched Description: … [L33110] They are both quaternary ammonium compounds and long acting muscarinic antagonists. ... found that glycopyrronium could also be used for reducing sweat gland,[L4755] oral,[L33140] airway, and ... L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and
Matched Categories: … Alimentary Tract and Metabolism ... formoterol and glycopyrronium bromide ... indacaterol and glycopyrronium bromide ... glycopyrronium bromide and psycholeptics ... formoterol, glycopyrronium bromide and budesonide …
Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within...
Approved
Matched Description: … 13-cis-retinoic acid (RA). ... [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and ... within neuroblastomas (and other neuroectodermal tumors),[A224609] and is rarely subject to antigen …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Approved
Investigational
Vet approved
Matched Description: … GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Gonadotropins and Antigonadotropins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Approved
Matched Description: … Nafarelin has been used in the treatments of central precocious puberty and endometriosis. …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Gonadotropins and Antigonadotropins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 2351 - 2375 of 15655 in total